1,980 results on '"MOK, Tony"'
Search Results
202. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
203. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
204. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
205. Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer
206. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
207. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
208. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
209. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
210. Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis
211. A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)
212. Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
213. Contributors
214. Systemic Options for Second-Line Therapy and Beyond
215. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)
216. Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer
217. Fast Drug Scheduling Optimization Approach for Cancer Chemotherapy
218. Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
219. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
220. Withdrawal of dacomitinib treatment due to absence of toxicities is not justified
221. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
222. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
223. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
224. A Detouring Experience Not Recommended: Lessons Learned from PF00299804
225. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide
226. Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition
227. Evolutionary Drug Scheduling Model for Cancer Chemotherapy
228. Management of non-small-cell lung cancer: recent developments
229. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
230. Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant
231. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
232. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
233. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
234. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma
235. Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1
236. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
237. Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review
238. Ethnic variation in response to EGFR inhibitors
239. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
240. O8-4 KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC
241. Abstract CT555: Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study
242. Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
243. Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).
244. Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
245. Tumor response heterogeneity, a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma.
246. Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC).
247. In Response to Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX
248. Affine Medical Image Registration with Coarse-to-Fine Vision Transformer
249. A novel parameter reflecting the interaction between CD8+ T cells and cancer-associated fibroblasts.
250. Low-dose selenite synergizes with KRAS inhibitor as a dual apoptotic and ferroptotic agent in lung adenocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.